Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,011 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Genitourinary System; Disorder, Female Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Extended CPAP on Bronchopulmonary Dysplasia

NCT05547139
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Prematurity
Interventions
Protocolized weaning of respiratory support
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
22 Weeks to 30 Weeks
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Not applicable Interventional Results available

A Feasibility Device Study to Prevent Female Urinary Stress Incontinence

NCT03010800
View directory record Official record
Conditions
Stress Incontinence, Female
Interventions
With Yoni.Fit, Without Yoni.Fit
Device
Lead sponsor
Watkins Conti Products. Inc.
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

NCT00471536
View directory record Official record
Conditions
Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
pazopanib hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
7
States / cities
Jacksonville, Florida • Baltimore, Maryland • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prevention of Postpartum Hemorrhage With Tranexamic Acid

NCT03287336
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Tranexamic Acid
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Jul 23, 2026, 6:36 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain

NCT01189071
View directory record Official record
Conditions
Overactive Bladder, Renal Colic, Pain, Postoperative
Interventions
Darifenacin
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Not applicable Interventional

OPTIONS: A Patient-Centered HIV Prevention Decision Aid for PrEP Uptake for Women With Substance Use in Treatment Settings

NCT03651453
View directory record Official record
Conditions
HIV Infections, Substance Abuse
Interventions
Decision aid, Standard care
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Not applicable Interventional

Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer

NCT01655745
View directory record Official record
Conditions
Bladder Cancer
Interventions
FDG PET/MR
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Jul 23, 2026, 6:36 PM EDT
Recruiting Phase 2 Interventional

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

NCT05796375
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
Cystoscopy, Bladder EpiCheck urine test, Xpert Bladder Cancer Monitor urine test
Procedure · Diagnostic Test
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
West Haven, Connecticut • Bay Pines, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 6:36 PM EDT
Withdrawn Not applicable Interventional

Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

NCT00298064
View directory record Official record
Conditions
Cervical Cancer, Cervix
Interventions
Tissue Repository
Genetic
Lead sponsor
University of New Mexico
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Jul 23, 2026, 6:36 PM EDT
Terminated Phase 4 Interventional Results available

Nesiritide and Renal Function After the Total Artificial Heart

NCT01836809
View directory record Official record
Conditions
Congestive Heart Failure, Cardiorenal Syndrome
Interventions
nesiritide, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

NCT00459875
View directory record Official record
Conditions
Kidney Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Jul 23, 2026, 6:36 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biomarkers Study in Infants With Prior Neonatal Brain Injury

NCT07413900
View directory record Official record
Conditions
HIE - Hypoxic - Ischemic Encephalopathy, Perinatal Anoxic-ischemic Brain Injury, Premature Birth, Healthy Participants
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
3 Months to 24 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 23, 2026, 6:36 PM EDT
Terminated Phase 2 Interventional Results available

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

NCT01215136
View directory record Official record
Conditions
Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
Interventions
Everolimus, Paclitaxel
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Chicago, Illinois • Bloomington, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 23, 2026, 6:36 PM EDT
Active, not recruiting No phase listed Observational

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)

NCT05520099
View directory record Official record
Conditions
Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder, Kidney Cancer, Clear Cell Renal Cell Cancer (ccRCC), Colorectal Cancer, MSI-H Colorectal Cancer, DMMR Colorectal Cancer, Head and Neck Cancer (H&N), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Liver Cancer, Hepatocellular Carcinoma (HCC), Lung Cancer (NSCLC), NSCLC (Non-small Cell Lung Cancer), Skin Cancer, Cutaneous Melanoma, Endometrial Cancer, Solid Tumor Cancer
Interventions
Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
Procedure
Lead sponsor
Elephas
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Salinas, California • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 3 Interventional

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

NCT00561093
View directory record Official record
Conditions
Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
Interventions
pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa)
Drug · Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Irvine, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

NCT04994522
View directory record Official record
Conditions
End Stage Renal Disease, Renal Impairment
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 23, 2026, 6:36 PM EDT
Not yet recruiting Phase 3 Interventional

Prophylactic Amnioinfusion for Prevention of Postpartum Hemorrhage

NCT06691945
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Saline delivered using an intrauterine pressure catheter (IUPC)
Combination Product
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Results available

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

NCT00234039
View directory record Official record
Conditions
Bladder Cancer
Interventions
gemcitabine hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
98
States / cities
Little Rock, Arkansas • Los Angeles, California • Leesburg, Florida + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Not applicable Interventional Results available

Prevention of Preterm Birth With a Pessary in Twin Gestations

NCT02056639
View directory record Official record
Conditions
Premature Birth, Short Cervix
Interventions
Bioteque cup pessary
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Identification of the Cranberry Juice Compounds That Prevent Urinary Tract Infections

NCT00087828
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Cranberry juice cocktail
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 64 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jul 23, 2026, 6:36 PM EDT
Completed No phase listed Observational

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

NCT04394234
View directory record Official record
Conditions
Uterine Hemorrhage
Interventions
Direct oral anticoagulant (DOACs), Warfarin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
961,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jul 23, 2026, 6:36 PM EDT
Not listed Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

NCT00003634
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
oregovomab
Biological
Lead sponsor
AltaRex
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
29
States / cities
Berkeley, California • Los Angeles, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

NCT02963831
View directory record Official record
Conditions
Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
Interventions
ONCOS-102, Durvalumab, Cyclophosphamide
Biological · Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
San Diego, California • Miami, Florida • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jul 23, 2026, 6:36 PM EDT